Navigation Links
Target in Biological Technology

Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3

FREMONT, Calif., May 11 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, "PF-04...

Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market

Changes Will Result in a 35% Sales Force Reduction and Approximately $45 Million Annual GAAP Operating Results Benefit SAN DIEGO, May 4 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today announced a new approach to sales within the diabetes market. Amylin's existin...

Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7

LELYSTAD, The Netherlands, April 6 /PRNewswire/ -- Today, Pepscan reports that it has achieved a major scientific breakthrough through the use of its CLIPS-based synthetic peptide immunogen technology. By constructing synthetic 3D mimics of the ligand binding-site on CXCR7 it has induced funct...

CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors

--By Avoiding the CNS, These Compounds May Be Free of the Side Effects Associated with Traditional Cannabinoid Compounds-- RESEARCH TRIANGLE PARK, N.C., April 1 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases o...

GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling

Leading Sucralose manufacturer Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd. (GDFII/L&P) today announced that the U.S. International Trade Commission (ITC) in Washington D.C. has extended the target date of its final decision in the sucralose case, from March 25 to April ...

Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia

MONTREAL, March 3 /PRNewswire/ -- Enobia Pharma, an emerging Canadian biotech company focused on developing novel therapeutics for serious bone disorders, today announced completion of target enrollment in its pilot clinical trial in infants suffering from a severe form of hypophosphatasia. Enobi...

Mosquito genes linked to insecticide resistance may be new target in fight against malaria

Malaria remains one of the most serious diseases worldwide, claiming the lives of more than one million people per year in tropical and sub-tropical regions, the majority of whom are children under five years of age. Efforts to eliminate this mosquito-borne illness rely heavily on prevention meas...

Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling

Findings Support Development of Micromet's EpCAM-specific Antibody Therapeutics BETHESDA, Md., Jan. 13 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune d...

Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products

PALM SPRINGS, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Dynamic Alert Limited (OTC Bulletin Board: DYMC) is pleased to announce that it has now identified its target markets for its pharmaceutical product line-up. The modalities will include a lozenge with some capacity for enhancing rapid onset th...

New Pharmaceutical Company to Target Alzheimer's Disease

SARASOTA, Fla., Oct. 21 /PRNewswire/ -- A team of world-renowned scientists today announced the launch of Archer Pharmaceuticals, Inc., a new company that will use modern technologies for the identification of novel treatments for Alzheimer's disease. Archer Pharmaceuticals, Inc., led by Chi...

Vista Partners Updates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx), Raises Target Price to AU$1.65

LOS ANGELES, Oct. 13 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on leading Australian biotechnology company Arana Therapeutics, (ASX: AAH; AIM: AAHx) and raised its target price to AU$1.65. "In our opinion, Arana differentiates itself from many competitors in t...

Vista Partners Updates Coverage; Maintains $3.20 Target Price

LOS ANGELES, Oct. 13 /PRNewswire/ -- Vista Partners announced today that it has updated its coverage on American Bio Medica Corporation (Nasdaq: ABMC ) and maintains its twelve month target price of $3.20. Ross Silver, Director of Research at Vista Partners stated, "Sales internationally cont...

Avalanche photodiodes target bioterrorism agents

Researchers have shown that a new class of ultraviolet photodiode could help meet the U.S. military's pressing requirement for compact, reliable and cost-effective sensors to detect anthrax and other bioterrorism agents in the air. "The military is currently using photomultiplier tubes, which a...

Avalanche photodiodes target bioterrorism agents

Researchers have shown that a new class of ultraviolet photodiode could help meet the U.S. military's pressing requirement for compact, reliable and cost-effective sensors to detect anthrax and other bioterrorism agents in the air. "The military is currently using photomultiplier tubes, which a...

Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease

Laboratory study shows naturally occurring antibodies contained in GAMMAGARD LIQUID may bind to the primary culprit for Alzheimer's disease CHICAGO, April 15 /PRNewswire-FirstCall/ -- The University of Tennessee Health Science Center and Baxter International Inc. (NYSE: BAX ) today annou...

Vista Partners Updates Coverage; Maintains $3.20 Target Price

LOS ANGELES, April 1, 2008 /PRNewswire/ -- Vista Partners announced today that it has updated its coverage on American Bio Medica Corporation (Nasdaq: ABMC ) and maintains its twelve month target price of $3.20. Ross Silver, Director of Research at Vista Partners stated, "Sales internationall...

BioMagnetics Diagnostics Corp. Rated 'Speculative Buy,' Target Price $1.42 by Beacon Equity Research

DALLAS, March 13 /PRNewswire/ -- BioMagnetics Diagnostics Corp. (Pink Sheets: BMGP) has been rated Speculative Buy with a price target of $1.42 by Beacon Equity Research Analyst, Lisa Springer, CFA. The full report is available at http://www.BeaconEquity.com . Anyone interested in receivi...

PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008

ANNAPOLIS, Md., March 6 /PRNewswire-FirstCall/ -- PharmAthene, Inc., a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that it has completed the initial pharmacokinetic (PK) testing of ...

Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity

- Data Further Supports High Degree of Tumor Targeting Specificity for Bavituximab, Currently in Phase II Cancer Trials in Combination with Chemotherapy - - Imaging Study Also Suggests Potential Utility of Anti-PS Agents for Molecular Imaging ...

Foamix Signs Term Sheet to Acquire License to Organo-Boron Antifungal Molecules - Will Target the $11 Billion Dollars Fungal Infection Market

NESS ZIONA, and TEL AVIV, Israel, January 31 /PRNewswire/ -- Foamix Ltd. a leading worldwide developer of topical foams for dermatology and gynecology and Ramot at Tel Aviv University Ltd., have reached an agreement on the commercial terms of a worldwide exclusive license for Organo-Boron Anti...

Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally

OLATHE, Kan., Jan. 15 /PRNewswire-USNewswire/ -- The Kansas Bioscience Authority has launched a $2.5 million initiative to bring together researchers nationwide to create products that protect Americans from the intentional use of animal-borne diseases to disrupt the national economy or to inf...

Researchers use magnetism to target cells to animal arteries

Scientists have used magnetic fields and tiny iron-bearing particles to drive healthy cells to targeted sites in blood vessels. The research, done in animals, may lead to a new method of delivering cells and genes to repair injured or diseased organs in people. The study team, led by Robert J. ...

New target for anti-flu drug development

Boston, August 15, 2007---Scientists at Cure Lab, Inc., a biotechnology company based in Canton, Massachusetts, in collaboration with researchers at Boston University and Harvard Medical School have discovered a potential new target for the development of anti-influenza (flu) drugs, including thos...

Genmab Discloses Target and Development Plans for HuMax-Inflam

Summary: Genmab Reveals That HuMax-Inflam Target is IL-8 and Future Development Will be in Cancer and Inflammation COPENHAGEN, September 13 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today its fully human HuMax-Inflam(TM) antibody is directed to IL-8 (interleukin-8...

Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price

BOCA RATON, Fla., Aug. 29 /PRNewswire/ -- Dawson James Securities, a full- service investment firm serving the healthcare and biotechnology industry, initiated research coverage on CryoCor, Inc. (Nasdaq: CRYO ) with a Strong Buy rating and a 12-18 month price target of $6.00. John M. Putnam, ...

Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome

BOSTON and THE WOODLANDS, Texas, Aug. 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) presented data today describing the structure-activity relationship (SAR) of a class of internally-developed compounds that includes LX1031 and other compounds under evaluation by ...

Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target

SEATTLE, Jan. 6 /PRNewswire/ -- Omeros Corporation today announced that The Michael J. Fox Foundation has awarded it a $465,000 grant against milestones to support the Company's collaboration with The Parkinson's Institute to evaluate Omeros' recent discovery of a new target for the treatment of P...

Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target

KING OF PRUSSIA, Pa., Aug. 18 /PRNewswire/ -- Emerging Growth Equities, Ltd. initiates coverage of CombiMatrix Corporation (Nasdaq: CBMX ) with a BUY rating and an $18.00 price target. CombiMatrix is a life sciences company focused on developing and commercializing in vitro genetic diagnostic...

Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target

LOS ANGELES, Aug. 6 /PRNewswire/ -- Vista Partners announced today that it has updated coverage and has issued a $3.57 price target on Inovio Biomedical Corporation (Amex: INO ). "The proposed merger of Inovio and VGX would create a comprehensive DNA company that can create and deliver therap...

Symmetry Medical Extends 10-K Filing Beyond April 14, 2008 Target

WARSAW, Ind., April 14 /PRNewswire-FirstCall/ -- Symmetry Medical Inc. (NYSE: SMA ), a leading independent provider of products to the global orthopedic device industry and other medical markets, today announced that the filing of its 2007 Annual Report on Form 10-K with the Securities and Ex...

Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target

LOS ANGELES, March 5 /PRNewswire/ -- Vista Partners announced today that it has updated coverage and has issued a $3.52 price target on Inovio Biomedical Corporation (Amex: INO ). "Inovio has compelling pre-clinical and clinical data regarding the ability of their technology to significantly ...

Coherent Sets Future Financial Target

SANTA CLARA, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Coherent, Inc. (Nasdaq: COHR ), a leading supplier of lasers and electro-optics for commercial and scientific applications, announced an adjusted EBITDA target of 19-23% of sales exiting fiscal year 2010. The Company intends to achieve ...

Fiserv Launches Avidyn Health to Target Healthcare Costs

Brookfield, Wis. - Fiserv Health, an operating group of Fiserv, Inc. has announced the launch of Avidyn Health, a care management company targeting the self-funded health care market. Fiserv Health provides independent health plan management, claims processing and administration services fo...

Offshore Outsourcing: On Target or Off Base?

Im not a big Bob Dylan fan, but lately I cant help thinking of the second verse from "Blowin' in the Wind" in which he questions mans inability to confront what is really happening all around him. Dylans lyrics come to mind whenever the media starts hyping yet another new business imperative....

Third Wave co-founder shoots for small target in latest project

Madison, Wis. Researchers led by James Dahlberg, a founder of Madison-based bioscience company Third Wave Technologies , have found that a super-small genetic element may play a critical role in the development of certain types of cancer. Teams led by Dahlberg and collaborator Wayne Tam at t...

ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications

ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications Introduction ESR1 (Estrogen Specific Receptor 1) is a member of the nuclear hormone receptor (N...

Feasibility of Multiplexing Bio-Plex Total Target and Phosphoprotein Assays

Qian Gao, Joella Blas, and Efthalia Gerasimopoulos, Bio-Rad Laboratories, Inc., Hercules, CA 94547 USA Introduction Bio-Plex assays allow detection of mutiple target proteins in a small volume of sample. The assays are based on detect...

Protect RNA and Improve Target Cell Identification

LCM Staining Kit Reagents and protocols optimized to minimize endogenous RNase activity Superior identification of target cells provided by histological and fluorescent stains Desig...

Gene Expression Arrays: Highly Sensitive Detection of Expression Patterns with Improved Tools for Target Amplification

Introduction As the human genome project is completed, microarray technology offers the potential to study the genomes complexity. This technology facilitates the direct ext...

Microarray Target Purification Kit and the Microarray Target Synthesis Kit (T7)

As the human genome sequence project is completed, the vast amount of genomic information calls for methods that allow gene expression analysis on a genomic scale and speed up detection of significant sequence variation...
Other Tags
(Date:7/11/2014)... to study the proteins that let nerve cells send ... stumbled upon a biological tactic that may offer a ... a safe and environmentally responsible way. , Their ... one species and harmless for a closely related onesuggests ... without harming beneficial species like bees. A summary of ...
(Date:7/10/2014)... Fe, Albuquerque, and other major cities in New Mexico, ... treated municipal wastewater rather than precious potable water supplies. ... 40% of all golf courses receive treated effluent. Reusing ... , Additionally, golf courses and homeowners alike fertilize their ... fertilizer is nitrate. A New Mexico State University turfgrass ...
(Date:7/10/2014)... , June 27, 2014  Pomerantz LLP ... Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) and ... in United States District Court, Middle District of ... on behalf of a class consisting of all ... Provectus securities between December 17, 2013 and May ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3'Tailored' water -- the latest in lawn care 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
(Date:7/12/2014)... Using and carrying around a catheter ... from Ashland, Va., decided that there needed to be ... to conceive of our design," he said. , They ... which provides an inconspicuous way to use and carry ... as promotes comfort and peace of mind. Producible in ...
(Date:7/12/2014)... July 12, 2014 “Critical Care ... New and Late-Stage Four-Factor PCCs and Recombinant Products ... the critical care market in the US, UK, ... report provides an estimation of market size for ... covers critical care indications that are being treated ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 A recent article ... provides a trio of suggestions for those seeking cosmetic ... days are rapidly approaching and the heat begins to enliven ... to their summer clothing, realizing that they didn’t work out ... , This can cause a sudden surge of people eager ...
(Date:7/12/2014)... Maxim Peptide, a website that features ... solely in scientific experiments, is currently celebrating its second ... Maxim Peptide, which was created by the founders of ... updated website that now features a special deals section. ... with fascinating articles about peptide research, including a new ...
(Date:7/11/2014)... July 11, 2014 The American Association ... 55 poison centers are commending Senator Bill Nelson (D-FL) ... Act of 2014 on July 10, 2014. Along with ... Products Safety Commission (CPSC) to enact rules requiring safer, ... , Senate co-sponsors of the bill include: ...
Breaking Medicine News(10 mins):Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3
Other Contents